The expression of GzmB was also significantly higher in CD8+ T lymphocytes from patients treated with FTY (43.2, mean; 95% CI) (p = 0.0163) and NTZ (40.5, mean; 95% CI) (p = 0.0048) vs. healthy donors, but not in treated RRMS patients during first-line immunomodulatory therapies, GA and IFN (26.8 and 25.5, means; 95% CI) nor in untreated RRMS patients (31.9, mean; 95% CI) vs. healthy donors, respectively (Figure 1E). This evidence concerns the gene CD8A and relapsing-remitting multiple sclerosis.